• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类血管组织中的一种激肽释放酶样酶。

A kallikrein-like enzyme in human vascular tissue.

作者信息

Madeddu P, Gherli T, Bacciu P P, Maioli M, Glorioso N

机构信息

Clinica Medica, Sassari University, Italy.

出版信息

Am J Hypertens. 1993 May;6(5 Pt 1):344-8. doi: 10.1093/ajh/6.5.344.

DOI:10.1093/ajh/6.5.344
PMID:8512658
Abstract

We attempted to identify the presence of kallikrein in human vascular tissue obtained from patients undergoing surgery. Sections of thoracic (n = 9) and abdominal aorta (n = 6), renal artery (n = 6), and saphenous vein (n = 17) were rinsed with 0.01 mol/L Tris-HCl buffer, cleaned, minced, and homogenized at 4 degrees C. The homogenates were centrifuged and supernatants were assayed for protein content and for active and total (trypsin activation) enzymatic activity on the peptide H-D-Val-Leu-Arg-paranitroanilide (S2266), a synthetic substrate for glandular kallikrein. Enzymatic activity was inhibited by aprotinin and polyclonal antibodies against human glandular kallikrein. Kallikrein was resistant to soybean trypsin inhibitor and had an optimum pH of 8.2. A significant correlation was found between the amidolytic and kininogenase activities measured on S2266 and dog kininogen, respectively (r = 0.83, P < .01). The kallikrein-like enzyme was present mainly in the inactive form. Higher levels were found in the homogenates of renal artery (active: 190 +/- 36, total: 5036 +/- 908 pkat/g protein) than in those of thoracic (active: 38 +/- 9, total: 973 +/- 350 pkat/g protein) and abdominal aorta (active: 44 +/- 10, total: 3031 +/- 709 pkat/g protein). In the homogenates of saphenous vein, active and total enzymatic activities averaged 188 +/- 90 and 2003 +/- 450 pkat/g protein, respectively. A significant inverse correlation was found between the levels of total enzymatic activity in saphenous vein homogenates and mean blood pressure values (r = 0.78, P < .005). These results suggest that a kallikrein-like enzyme is present in human vasculature.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们试图在接受手术患者的人体血管组织中鉴定激肽释放酶的存在。将胸主动脉(n = 9)、腹主动脉(n = 6)、肾动脉(n = 6)和大隐静脉(n = 17)的切片用0.01 mol/L Tris-HCl缓冲液冲洗,清理、切碎并在4℃下匀浆。匀浆经离心后,取上清液测定蛋白质含量以及对肽H-D-缬氨酸-亮氨酸-精氨酸-对硝基苯胺(S2266,一种腺激肽释放酶的合成底物)的活性和总(胰蛋白酶激活)酶活性。酶活性被抑肽酶和抗人腺激肽释放酶的多克隆抗体抑制。激肽释放酶对大豆胰蛋白酶抑制剂有抗性,最适pH为8.2。分别在S2266上测得的酰胺水解活性与狗激肽原酶活性之间发现显著相关性(r = 0.83,P <.01)。类激肽释放酶主要以无活性形式存在。肾动脉匀浆中的水平(活性:190±36,总:5036±908 pkat/g蛋白质)高于胸主动脉(活性:38±9,总:973±350 pkat/g蛋白质)和腹主动脉(活性:44±10,总:3031±709 pkat/g蛋白质)。在大隐静脉匀浆中,活性和总酶活性分别平均为188±90和2003±450 pkat/g蛋白质。在大隐静脉匀浆中的总酶活性水平与平均血压值之间发现显著负相关(r = 0.78,P <.005)。这些结果表明人体血管系统中存在类激肽释放酶。(摘要截短于250字)

相似文献

1
A kallikrein-like enzyme in human vascular tissue.人类血管组织中的一种激肽释放酶样酶。
Am J Hypertens. 1993 May;6(5 Pt 1):344-8. doi: 10.1093/ajh/6.5.344.
2
Characterization of a new kallikrein-like enzyme (KLP-S3) of the rat submandibular gland.大鼠下颌下腺一种新的激肽释放酶样酶(KLP-S3)的特性研究。
Biochem J. 1992 Feb 1;281 ( Pt 3)(Pt 3):819-28. doi: 10.1042/bj2810819.
3
Increased kallikrein activity in the rabbit renal vasculature during low sodium intake.低钠摄入期间家兔肾血管中激肽释放酶活性增加。
Clin Exp Pharmacol Physiol. 1997 Feb;24(2):153-6. doi: 10.1111/j.1440-1681.1997.tb01799.x.
4
Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein.来自大鼠血管组织的一种类似组织激肽释放酶的激肽原酶的特性分析。
Circ Res. 1985 Jun;56(6):816-21. doi: 10.1161/01.res.56.6.816.
5
Kininogenase from rat vascular tissue.来自大鼠血管组织的激肽原酶。
Adv Exp Med Biol. 1986;198 Pt A:11-7. doi: 10.1007/978-1-4684-5143-6_2.
6
[Specificity of the determination of urinary kallikrein activity using an amidolytic assay].
Rev Esp Fisiol. 1983 Sep;39(3):225-30.
7
Glandular kallikrein-like enzyme in adrenal glands.肾上腺中的腺激肽释放酶样酶。
Adv Exp Med Biol. 1989;247B:217-22. doi: 10.1007/978-1-4615-9546-5_36.
8
Developmentally regulated kallikrein enzymatic activity and gene transcription rate in maturing rat kidneys.发育调控的激肽释放酶活性及成熟大鼠肾脏中的基因转录率
Am J Physiol. 1993 Jul;265(1 Pt 2):F146-50. doi: 10.1152/ajprenal.1993.265.1.F146.
9
Use of different derivatives of D-Val-Leu-Arg for studying kallikrein activities in cat submandibular glands and saliva.使用D-缬氨酸-亮氨酸-精氨酸的不同衍生物研究猫下颌下腺和唾液中的激肽释放酶活性。
Histochem J. 1985 Jul;17(7):805-18. doi: 10.1007/BF01003316.
10
A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats.单肾单夹高血压大鼠血管中的一种激肽释放酶样酶。
Hypertension. 1990 Oct;16(4):436-40. doi: 10.1161/01.hyp.16.4.436.

引用本文的文献

1
Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.人组织激肽释放酶在胃肠道间质瘤侵袭中的作用。
Br J Cancer. 2010 Oct 26;103(9):1422-31. doi: 10.1038/sj.bjc.6605906. Epub 2010 Sep 21.
2
Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement.系统性硬化症中循环组织激肽释放酶水平升高与微血管受累相关。
Ann Rheum Dis. 2005 Mar;64(3):382-7. doi: 10.1136/ard.2004.023382.
3
AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions.
在血流条件下,AT(2)受体依赖性血管舒张是由血管激肽生成的激活介导的。
Br J Pharmacol. 2002 Jun;136(4):484-91. doi: 10.1038/sj.bjp.0704731.
4
Endothelial AT(2)-receptors: chicken or egg?内皮细胞的血管紧张素Ⅱ2型受体:先有鸡还是先有蛋?
Br J Pharmacol. 2002 Jun;136(4):481-3. doi: 10.1038/sj.bjp.0704763.
5
Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse.激肽在卡托普利诱导的对小鼠颈动脉血流中断所致内膜增生的抑制作用中的参与情况。
Br J Pharmacol. 2000 Jul;130(5):1076-82. doi: 10.1038/sj.bjp.0703388.
6
Somatic cell gene therapy for a trait as complex as hypertension?针对像高血压这样复杂的性状进行体细胞基因治疗?
J Clin Invest. 1995 Apr;95(4):1426. doi: 10.1172/JCI117811.
7
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.人组织激肽释放酶的直接基因递送可降低自发性高血压大鼠的血压。
J Clin Invest. 1995 Apr;95(4):1710-6. doi: 10.1172/JCI117847.